A good insurance card can create a quiet kind of confidence. If a treatment mattered, surely someone would have mentioned it. If it were covered, surely it would be easy. If it were legitimate, surely you would have heard of it by now.

Those assumptions are understandable. For people with commercial coverage who are living with depression that standard medication has not fixed, several of them are also wrong. This myth-check weighs the most common ones against what 443 Midwest adults told our commissioned survey.

Myth: "If it were a real option, I would have heard of it."

Reality: Almost nobody has. Seventy-three percent of respondents, nearly three in four, had no knowledge of Spravato, which puts esketamine in a nasal spray and is FDA-approved for adults whose earlier depression treatments fell short. One in five knew the name without knowing what it was. Just 6 percent could describe it.

Low awareness says little about legitimacy. It reflects how the treatment is typically discussed: in doctors' offices, rarely in public. These are final, validated figures. Commercial insurance did not buy awareness either: in that group of 173 respondents, 74 percent drew a blank on the brand.

Myth: "My doctor would have brought it up if it made sense for me."

Reality: Maybe, maybe not. Busy appointments often focus on adjusting the current medication. Patients who do not know an option exists cannot ask about it, and our survey suggests most do not. The good news is that people trust their doctors deeply. Of the voices we listed, their own doctor's would move 74 percent of respondents toward a new treatment, more than any other. That trust makes it worth asking directly: "Is esketamine something you would consider for me?" Before that visit, a plain overview of Spravato can help you frame the question.

Myth: "Commercial insurance covers everything my doctor prescribes."

Reality: Coverage for esketamine varies by plan and almost always comes with conditions. Many commercial plans require prior authorization, usually with documentation that you have tried at least two antidepressants without enough improvement. Some plans handle it under the medical benefit, others through a specialty pharmacy, and the difference affects your costs.

Coverage matters to people. Of our respondents, 85 percent put it on their two-item list of provider priorities. The practical step is to check, not assume: call member services, and ask whether the treatment is covered, what the criteria are, and which certified centers are in network.

Myth: "A prior authorization means the answer is probably no."

Reality: Prior authorization is a checkpoint, not a rejection. It often comes down to documentation. Keeping a running list of each antidepressant, its dose, dates, and reasons for stopping, makes approval easier. Just over half our respondents said they would accept extra hoops to keep a treatment covered, rather than pay out of pocket for simplicity. Knowing what the hoops are makes them far less intimidating.

Myth: "If I get denied, that is final."

Reality: Commercial plans must offer an internal appeal, and many situations also qualify for an independent external review. Your doctor can often request a peer-to-peer conversation with the insurer's reviewer. Many initial denials are overturned once missing information is supplied. Ask for the denial reason in writing, then work with your doctor on the response.

Myth: "Esketamine and the ketamine I see online are the same thing."

Reality: They are different drugs used in different ways. Esketamine, which Spravato contains, is FDA-approved for depression that has resisted treatment, and it is administered only at certified sites, where staff monitor you after each dose and you cannot drive home. Ketamine used for depression, whether by IV infusion or at-home telehealth programs, is off-label, frequently cash-pay, and in the at-home case involves much less supervision.

Commercial plans are more likely to cover the FDA-approved option. Do not assume that one being covered means the other is, or that one being available online means it is equivalent.

Myth: "The manufacturer's copay card works for everyone."

Reality: The manufacturer's patient support program has offered cost help to some commercially insured patients, but eligibility rules apply, and manufacturer copay assistance generally excludes people on government programs such as Medicare and Medicaid. Some employer plans also have rules about how copay assistance counts toward your deductible. Ask both the program and your insurer how it would work for you.

Myth: "I can do this on my lunch break."

Reality: Each session includes the dose and a monitoring period afterward, and driving has to wait for the following day. The early phase involves more frequent visits. Plan for time and transportation. Nearness ranked second among priorities in our survey, at 43 percent, for good reason. If you work full time, ask centers about early or late appointments, and ask HR whether leave protections might apply.

Myth: "Most people would be against something like this."

Reality: Most people are cautious, not opposed. Hearing the words ketamine therapy for the first time, 34 percent of respondents said they felt cautious but open, and 18 percent said hopeful or curious. Only 9 percent were negative. For 59 percent, FDA approval was deciding or big, which is one more reason to be clear about which treatment you are discussing.

What to take from this

  • Not having heard of esketamine is normal. It does not mean it is fringe.
  • Your insurance may cover it when criteria are met. Find out, rather than guessing.
  • Documentation of past medications is the key that opens most coverage doors.
  • Denials can be appealed.
  • FDA-approved esketamine and off-label ketamine are separate choices.
  • The call on whether it suits you belongs to your own clinician, not to an insurer or a website.

If your depression has reached the point of thinking about suicide, put all of this on hold and get help now; 988 calls and texts go to the Suicide and Crisis Lifeline all day and night with no insurance required; veterans can press 1.

Methodology

Our figures come from 443 completed Pollfish consumer panel responses, gathered through June 23, 2026, from respondents aged 18 to 64 with homes in Ohio, Wisconsin, Iowa, Kansas, Missouri, Indiana, Oklahoma, Nebraska, Minnesota, and Illinois. We cite overall percentages plus one commercial-insurance breakdown. All figures come from the panel's completed validation. Our publisher commissioned the study and underwrote its cost. This is not medical or insurance advice.